Pelvic extraperitoneal IMT with malignant transformation in 14-year-old

Inflammatory myofibroblastic tumor (IMT) is an uncommon benign neoplasm with locally aggressive behavior but malignant change is rare. Such a rare tumor occurring in a 14-year-old patient with clinical presentations of abdominal pain and body weight loss was seldom described before.

A research article to be published on June 7, 2010 in the World Journal of Gastroenterology addresses this question. A research team led by Professor Ko from Chang Gung University College of Medicine, Chang Gung Memorial Hospital-Kaohsiung Medical Center, Taiwan, reported that computed tomography was useful for clear delineation of this huge pelvic-abdominal mass with extraperitoneal origin and prominent peritumoral vascularity which was crucial for surgical planning. Subsequent surgery, histopathology, immunohistochemistry, DNA sequencing and electron microscopy confirmed the final diagnosis of inflammatory myofibroblastic tumor with malignant transformation. Despite radical tumor resection, rapid tumor recurrence occurred in the lower abdomen 20 d after discharge.

This report documents the first known case of pelvic extraperitoneal IMT with malignant transformation in a pediatric patient. In light of this case, IMT should be considered in the differential diagnosis of pelvi-abdominal mass with large central necrosis and the presence of prominent peritumoral vascularity may also be a clue of high metabolic demand and even malignant transformation.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Anti-obesity drugs show promise in improving cardiovascular health beyond weight loss